Perrigo Confirms First To File Patent Challenge For Generic Version Of ProAir HFA Inhalation Aerosol

Perrigo Company PRGO TASE announced that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) for albuterol sulfate HFA inhalation aerosol, the generic version of ProAir® HFA. The ANDA filing involved contributions from both Perrigo and Catalent Pharma Solutions, Inc., who partnered on the development of this project.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: NewsFDALegal
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!